This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Forxiga (dapagliflozin) for the treatment of adults with chronic kidney disease (CKD). ... could be approximately 373, 000 adults living with the
Forxiga is the first ever approved medicine for the treatment of the disease in Japan. ... Ono Pharmaceutical has distribution rights for Forxiga in Japan and will co-promote the drug for the treatment of CKD along with AstraZeneca.
That includes Novartis’ Entresto (sacubitril/valsartan), which demonstrated 20% overall reduction in deaths or hospitalisations, and AstraZeneca’s Farxiga/Forxiga (dapagliflozin) which had a 26% improvement in cardiovascular death and worsening
Farxiga (dapagliflozin), sold under the brand name Forxiga in the UK, has scored a fast-track designation and is aiming for approval to reduce the risk of hospitalisation for heart failure
Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also
from AstraZeneca’s Farxiga/Forxiga (dapagliflozin) and Johnson &Johnson’s Invokana (canagliflozin).
More from news
Approximately 17 fully matching, plus 49 partially matching documents found.
receiving treatment with SGLT-2 inhibitors, including AstraZeneca’s Forxiga (dapagliflozin).
AstraZeneca is putting its confidence in UK infrastructure to the test in a pragmatic trial designed to compare the effectiveness of diabetes drug Forxiga to the standard of care.
targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.
Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.
Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...